Minaris Selects Apprentice’s Tempo to Scale Commercial Production

We’re excited to announce our latest partnership with Minaris Regenerative Medicine.

Discover how this partnership is set to revolutionize speed, cost efficiency, and customer experience, ultimately benefiting patients in need of cutting-edge therapies.

In this blog post, we’ll delve into how the adoption of Apprentice's Tempo Manufacturing Execution System (MES) is transforming the commercial manufacturing process in the life sciences industry. 

Minaris + Apprentice = A Cutting-Edge Collaboration

A leading CDMO focused on cell and gene therapies, Minaris has selected Apprentice's Tempo Manufacturing Execution System (MES) to digitize its commercial manufacturing in North America and Japan.

Minaris will use Tempo MES to increase speed-to-market, reduce costs, and deliver a superior customer experience.

These improvements will accelerate complex commercial batches so patients in need of cutting-edge cell and gene therapies can receive reliable treatment faster.

“Our technology has the unique features needed to break down the barriers that have held back commercial-scale cell and gene therapy manufacturing.

We are excited to partner with a pioneer like Minaris, whose mission is to eliminate the roadblocks between patients and the life-altering therapies they need.”

— Angelo Stracquatanio, Apprentice CEO & Co-Founder

U.S. to Japan: What’s in Store for 2024

In 2023, Minaris will begin deployment with a cell therapy drug product for a prevalent disease at their commercial site in Allendale, New Jersey, before implementing at their remaining sites in North America and Japan in 2024.

Minaris expects Tempo MES to:

• Increase speed-to-market delivery by eliminating the manual hours spent on cumbersome paper batch records and expediting batch record review time through a 'review by exception' approach.
• Reduce overall costs and risk of human errors by guiding operator execution through process control guardrails, enforcement of procedure step sequence, and automated calculations.
• Give Minaris customers a superior experience with real-time viewing access to and direct collaboration with their batch runs.

Apprentice's streamlined approach to deployment and GxP validation paired with its no-code platform make it faster and easier to deploy compared to traditional MES projects.

With the implementation of our cutting-edge Tempo Manufacturing Execution System (MES), expect remarkable improvements in speed-to-market, cost reduction, and customer experience.

“The potential of regenerative medicine is constrained by the pace, scale, and quality of commercial manufacturing.

With Apprentice's Tempo MES, we replace manual, paper systems with a digital system purpose-built for the commercial production of cell therapies.”

— Prakash Manwani, Chief Digital Officer, Minaris

About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies.

Minaris offers their clients high-value clinical and commercial manufacturing services, development solutions, and technologies. They are pioneers in the field with more than 20 years' experience providing outstanding quality and reliability.

Part of the Resonac Group, Minaris has facilities across North America, Europe, and Asia to support their mission of supplying life-changing therapies to patients globally.

“We share Apprentice's vision of a digitally connected manufacturing network that can unify and accelerate end-to-end production. Making that vision a reality at Minaris means miracle therapies can be more widely accessible to patients in need.”

— Prakash Manwani, Chief Digital Officer, Minaris

Watch Our Partnership Video

Want to see the magic in action? We’ve got you covered. Witness firsthand how this game-changing collaboration accelerates the delivery of reliable treatments to patients in need:

This is just the first step; we can’t wait to see what unfolds in the new year and beyond.

Stay tuned for continued updates and innovations reshaping the commercial manufacturing landscape in the life sciences industry.

Want to find out more? Read our press release to learn more about this exciting new partnership and what it means for the next era of Pharma 4.0.